CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 4, 2019-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on March 6, 2019 at 8:30 a.m. ET to discuss fourth quarter and full year 2018 results and provide a general business update.
- Focusing resources on clinical readouts from late-stage microbiome programs for ulcerative colitis, C. difficile infection and planned immuno-oncology study - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 7, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced certain corporate changes to
- Eric Shaff , previously Chief Operating and Financial Officer, appointed President and Chief Executive Officer - - Roger J. Pomerantz , M.D., to continue to serve as Chairman - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 15, 2019-- Seres Therapeutics, Inc .
– Recent FDA correspondence indicates this SER-287 Phase 2B study may support Biologics License Application (BLA) – – Company has received $40 million in milestone payments with Phase 2B study start – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 3, 2019-- Seres Therapeutics, Inc .
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 9, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will present at the Stifel 2018 Healthcare Conference in New York, NY on Tuesday, November 13 th at 9:30 a.m. ET . A live audio webcast of the presentation will be available under the
- Kevin Horgan , M.D. an accomplished drug developer and immunology expert, hired as Chief Medical Officer - - Planning for two new microbiome clinical studies in ulcerative colitis and metastatic melanoma; Company expects to receive $40M in payments from Nestlé Health Science with SER-287 Phase 2b
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 5, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on November 8, 2018 at 8:30 a.m. ET to discuss third quarter 2018 results and provide a general business update.
Dr. Horgan, an immunology and oncology drug development expert, is well positioned to drive Seres microbiome clinical programs forward CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 22, 2018-- Seres Therapeutics, Inc . (Nasdaq:MCRB) today announced the appointment of Kevin Horgan , M.D., as Executive
Findings support SER-109 Phase 3 program as a potential new treatment option for C. difficile infection CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 3, 2018-- Seres Therapeutics, Inc . (Nasdaq:MCRB) today announced it will present new data for SER-109, a microbiome candidate in Phase 3 development, at
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 4, 2018-- Seres Therapeutics, Inc . (Nasdaq:MCRB) today announced the appointment of Meryl Zausner , a seasoned biopharmaceutical executive, to its Board of Directors. Ms. Zausner brings decades of financial and operational leadership experience in the
